FDA Grants Belantamab Mafodotin Priority Review for Myeloma
The FDA granted priority review to the biologics license application of belantamab mafodotin for the treatment of patients with relapsed or refractory multiple myeloma...
Adding Isatuximab to Dexamethasone-Pomalidomide Combination Improves Progression-Free Survival in Pretreated Myeloma
Treatment with the investigational anti-CD38 monoclonal antibody isatuximab plus the combination of pomalidomide and low-dose dexamethasone (Pd) led to a median progression-free survival (PFS)...
Extinguishing Smoldering Myeloma?
For patients with smoldering myeloma – a precursor stage of multiple myeloma (MM) – the standard approach for years has been “watch and wait,”...
Daratumumab-Based Induction and Response-Adapted Consolidation Induces MRD Negativity in Patients With Newly Diagnosed Myeloma
Induction therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) followed by autologous transplant and Dara-KRd consolidation guided by measurable residual disease (MRD) leads to...
Clarithromycin Improves Responses But Fails to Prolong Survival in Newly Diagnosed Myeloma
Adding the antibiotic clarithromycin to lenalidomide plus dexamethasone improved the response rate in patients with multiple myeloma (MM), compared with lenalidomide and dexamethasone (Rd)...
Can Biomarkers Predict Myeloma Patients’ Response to Venetoclax?
In an analysis of the phase III BELLINI trial, researchers identified 2 biomarkers that predict response to venetoclax in patients with relapsed/refractory multiple myeloma...
ALCYONE Update: Adding Daratumumab to VMP Improves Survival in Transplant-Ineligible Myeloma
In patients with newly diagnosed multiple myeloma (MM) who are ineligible for high-dose chemotherapy and transplantation, adding daratumumab to bortezomib, melphalan, and prednisone (VMP)...
Lenalidomide Treatment Delays Progression From Smoldering to Symptomatic Myeloma
Observation is the standard approach to managing most patients with smoldering multiple myeloma (MM), but results from a phase III study suggest that early...
Early-Phase Trial Suggests Bispecific Antibody CC-93269 Has Activity in Relapsed/Refractory Multiple Myeloma
Watch our interview with Luciano J. Costa, MD, PhD.
CC-93269, a bispecific antibody that binds B-cell maturation antigen (BCMA) on malignant plasma cells and CD3...
Daratumumab, Carfilzomib, and Dexamethasone Combination Improves PFS in Patients with Relapsed/Refractory Multiple Myeloma
Adding daratumumab to a combination of carfilzomib and dexamethasone (KdD) led to a 37% improvement in progression-free survival (PFS), compared with carfilzomib and dexamethasone...
Current Issue
March 2020, Volume 6, Issue 4
This issue looks at how cost-effective analyses are used to inform health-care decisions, explains the latest maintenance of certification requirements, and more.
